The use of radiofrequency ablation for the treatment of benign and malignant tumors is a new technology that emerged in the early 1990’s. In 1990, McGahan and Rossi successively reported the use of radiofrequency ablation for the treatment of hepatic tumors, and since then this technology has aroused widespread interest in the world. The clinical application of radiofrequency ablation has been carried out in various countries successively, and our department has carried out nearly one hundred cases of laparoscopic radiofrequency ablation of renal tumors with good surgical results, especially for small renal cancers of less than 3cm, which have a high risk of being treated by ordinary surgery. Route selection of radiofrequency ablation for renal tumors: At present, according to the different routes of radiofrequency electrodes reaching the tumor tissues, there are three kinds of routes: open, laparoscopic and percutaneous puncture. Among them, open and laparoscopic routes are operated under direct vision, which have the advantages of intuition, precise positioning, easy protection of adjacent organs, and desirable pathological biopsy, etc. Percutaneous method is simple and easy to repeat the treatment, economical, with a short recovery cycle, and easy to be accepted by patients; however, its limitation lies in the limitation by the location of the tumor and adjacent organs, and the operation is usually completed with the help of imaging technology, such as CT, MRI, ultrasound and other guides in the clinic. The operation is usually performed under the guidance of imaging technology such as CT, MRI, ultrasound, etc. Indications and contraindications of radiofrequency ablation for renal tumors: Radiofrequency ablation can be considered for renal cancer patients whose radical nephrectomy or partial nephrectomy of one kidney may lead to the risk of renal insufficiency, such as isolated renal cancer; resected renal cancer of one kidney with metastatic or new cancer in the opposite kidney; single metastatic renal cancer; bilateral renal cancers (especially renal multitumor syndrome with a family hereditary trend); and patients with multiple tumors, such as Von Hippel, with a family genetic tendency. patients, such as Von-Hippel-Lindau disease and hereditary papillary renal cancer). Recently, foreign scholars have shown that small kidney cancer can also be treated with radiofrequency ablation, and there is no obvious tumor residue and recurrence. Radiofrequency ablation can also be used for kidney cancer patients who are old and weak, with serious heart disease, diabetes, etc. who cannot bear anesthesia and surgical trauma, so that these patients who used to have “no cure” have a new treatment method. Coagulation dysfunction is the only absolute contraindication to RFA; relative contraindications include recent acute myocardial infarction or unstable angina pectoris, and severe acute infection.